Overview / Abstract: |
Anne Chiang, MD, PhD, Yale School of Medicine, a leading expert on small cell lung cancer, for an in-depth presentation on patient outcomes in extensive-small cell lung cancer. Dr. Chiang will present evidence-based advice regarding emerging therapies, strategies for targeted treatments and immunotherapy, optimization of individual patient treatment plans, managing adverse events, and much more! Start the activity now! An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 13% of cases are classified as small cell. Most patients present with advanced-stage disease, making systemic therapy the cornerstone of management (ACS, 2020). Unfortunately, responses are fleeting and therapeutic options are limited. The 5-year survival rate for patients with SCLC is a dismal 6%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2020; NCI, 2019). Learning Objectives: Discuss the pathophysiology of extensive-stage SCLC and emerging therapeutic targets |
Expiration |
Jun 29, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 CME | 1.0 MOC | 1.0 NCPD | 1.0 ILNA AMA PRA Category 1 Credit™ |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Anne Chiang, MD, PhD, Yale School of Medicine |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Merck. |
Keywords / Search Terms |
i3 Health i3 Health small cell lung cancer, sclc, i3 Health i3 Health, live webinar, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Live CE CME |